British healthcare firm GlaxoSmithKline has filed for US regulatory approval of its new type 2 diabetes drug albiglutide, which belongs to the same group of injectable GLP-1 receptor agonists as Byetta, Bydureon and Victoza .
GSK announced on Monday that it had submitted the once-weekly medication to the US Food and Drug Administration (FDA) for approval and confirmed that it also plans to seek European Union regulatory approval for the new product in 2013.
{iframe}http://www.diabetes.co.uk/news/2013/Jan/gsk-seeks-fda-approval-for-new-glp-1-agonist-93796793.html{/iframe}